贝伐单抗治疗遗传性出血性毛细血管扩张难治性胃肠道出血。

IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY

Case Reports in Gastrointestinal Medicine Pub Date : 2021-06-29 eCollection Date: 2021-01-01 DOI:10.1155/2021/2242178

Muaaz Masood, Michael Coles, Humberto Sifuentes

{"title":"贝伐单抗治疗遗传性出血性毛细血管扩张难治性胃肠道出血。","authors":"Muaaz Masood, Michael Coles, Humberto Sifuentes","doi":"10.1155/2021/2242178","DOIUrl":null,"url":null,"abstract":"Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder resulting in vascular malformations of several organs including the pulmonary, cerebral, and gastrointestinal systems. One sequela is recurrent gastrointestinal (GI) bleeding. Bevacizumab (Bev) is emerging as an effective treatment of recurrent gastrointestinal bleeding in HHT. Bev is a recombinant monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), an integral part of angiogenesis.","PeriodicalId":45645,"journal":{"name":"Case Reports in Gastrointestinal Medicine","volume":"2021 ","pages":"2242178"},"PeriodicalIF":0.6000,"publicationDate":"2021-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263270/pdf/","citationCount":"2","resultStr":"{\"title\":\"Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab.\",\"authors\":\"Muaaz Masood, Michael Coles, Humberto Sifuentes\",\"doi\":\"10.1155/2021/2242178\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder resulting in vascular malformations of several organs including the pulmonary, cerebral, and gastrointestinal systems. One sequela is recurrent gastrointestinal (GI) bleeding. Bevacizumab (Bev) is emerging as an effective treatment of recurrent gastrointestinal bleeding in HHT. Bev is a recombinant monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), an integral part of angiogenesis.\",\"PeriodicalId\":45645,\"journal\":{\"name\":\"Case Reports in Gastrointestinal Medicine\",\"volume\":\"2021 \",\"pages\":\"2242178\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2021-06-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263270/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Gastrointestinal Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2021/2242178\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Gastrointestinal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/2242178","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 2

摘要

遗传性出血性毛细血管扩张症(HHT)是一种常染色体显性遗传病，导致包括肺、脑和胃肠道系统在内的多个器官的血管畸形。一个后遗症是复发性胃肠道出血。贝伐单抗(Bevacizumab, Bev)正在成为治疗HHT复发性胃肠道出血的有效方法。Bev是一种抑制血管内皮生长因子(VEGF)的重组单克隆抗体，VEGF是血管生成的重要组成部分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

$Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab.$

查看原文本刊更多论文

Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab.

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder resulting in vascular malformations of several organs including the pulmonary, cerebral, and gastrointestinal systems. One sequela is recurrent gastrointestinal (GI) bleeding. Bevacizumab (Bev) is emerging as an effective treatment of recurrent gastrointestinal bleeding in HHT. Bev is a recombinant monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), an integral part of angiogenesis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Case Reports in Gastrointestinal Medicine GASTROENTEROLOGY & HEPATOLOGY-

自引率

0.00%

发文量

审稿时长

14 weeks